168 related articles for article (PubMed ID: 33876211)
1. Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.
de Jongh M; Eyck BM; van der Werf LR; Toxopeus ELA; van Lanschot JJB; Lagarde SM; van der Gaast A; Nuyttens J; Wijnhoven BPL
BJS Open; 2021 Mar; 5(2):. PubMed ID: 33876211
[TBL] [Abstract][Full Text] [Related]
2. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.
van Hagen P; Wijnhoven BP; Nafteux P; Moons J; Haustermans K; De Hertogh G; van Lanschot JJ; Lerut T
Br J Surg; 2013 Jan; 100(2):267-73. PubMed ID: 23180560
[TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone.
Robb WB; Messager M; Dahan L; Mornex F; Maillard E; D'Journo XB; Triboulet JP; Bedenne L; Seitz JF; Mariette C; ; ; ; ;
Br J Surg; 2016 Jan; 103(1):117-25. PubMed ID: 26511668
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy.
Fang HY; Chao YK; Chang HK; Tseng CK; Liu YH
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27878893
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
Noordman BJ; Wijnhoven BPL; Lagarde SM; Boonstra JJ; Coene PPLO; Dekker JWT; Doukas M; van der Gaast A; Heisterkamp J; Kouwenhoven EA; Nieuwenhuijzen GAP; Pierie JEN; Rosman C; van Sandick JW; van der Sangen MJC; Sosef MN; Spaander MCW; Valkema R; van der Zaag ES; Steyerberg EW; van Lanschot JJB;
BMC Cancer; 2018 Feb; 18(1):142. PubMed ID: 29409469
[TBL] [Abstract][Full Text] [Related]
6. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer.
Blackham AU; H Naqvi SM; Schell MJ; Jin W; Gangi A; Almhanna K; Fontaine JP; Hoffe SE; Frakes J; Venkat P; Pimiento JM
J Surg Oncol; 2018 Feb; 117(2):150-159. PubMed ID: 28833197
[TBL] [Abstract][Full Text] [Related]
7. The patterns and risk factors for relapse in oesophageal squamous cell cancers that achieve pathological complete response to neoadjuvant chemoradiotherapy.
Zhong J; Fang S; Chen R; Yuan J; Xie X; Lin T; Liu M; Liu Q; Fu J
Eur J Cardiothorac Surg; 2024 Jun; 65(6):. PubMed ID: 38810125
[TBL] [Abstract][Full Text] [Related]
8. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma.
Zhou N; Mitchell KG; Corsini EM; Truong VTT; Antonoff MB; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Ajani JA; Hofstetter WL
Br J Surg; 2021 Oct; 108(10):1207-1215. PubMed ID: 34095952
[TBL] [Abstract][Full Text] [Related]
9. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
10. Population-based study of treatment and outcome of recurrent oesophageal or junctional cancer.
Pape M; Vissers PAJ; Bertwistle D; McDonald L; Beerepoot LV; van Berge Henegouwen MI; Lagarde SM; Mook S; Mohammad NH; Jeene PM; van Laarhoven HWM; Verhoeven RHA
Br J Surg; 2022 Nov; 109(12):1264-1273. PubMed ID: 35998093
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
[TBL] [Abstract][Full Text] [Related]
12. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
[TBL] [Abstract][Full Text] [Related]
14. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.
Xi M; Hallemeier CL; Merrell KW; Liao Z; Murphy MAB; Ho L; Hofstetter WL; Mehran R; Lee JH; Bhutani MS; Weston B; Maru DM; Komaki R; Ajani JA; Lin SH
Ann Surg; 2018 Aug; 268(2):289-295. PubMed ID: 28628563
[TBL] [Abstract][Full Text] [Related]
15. Omitting surgery in esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.
Park J; Yea JW; Oh SA; Park JW
Radiat Oncol; 2021 Nov; 16(1):219. PubMed ID: 34775988
[TBL] [Abstract][Full Text] [Related]
16. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS).
Toxopeus E; van der Schaaf M; van Lanschot J; Lagergren J; Lagergren P; van der Gaast A; Wijnhoven B
Ann Surg Oncol; 2018 Aug; 25(8):2441-2448. PubMed ID: 29948420
[TBL] [Abstract][Full Text] [Related]
18. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Lordick F; D'Journo XB; Cerfolio RJ; Korst RJ; Novoa NM; Swanson SJ; Brunelli A; Ismail M; Fernando HC; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J;
J Clin Oncol; 2018 Sep; 36(27):2796-2803. PubMed ID: 30089078
[TBL] [Abstract][Full Text] [Related]
20. Effect of neoadjuvant chemoradiation on preoperative pulmonary physiology, postoperative respiratory complications and quality of life in patients with oesophageal cancer.
Elliott JA; O'Byrne L; Foley G; Murphy CF; Doyle SL; King S; Guinan EM; Ravi N; Reynolds JV
Br J Surg; 2019 Sep; 106(10):1341-1351. PubMed ID: 31282584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
